Tags : Autoimmune

BioMed Collaborates with Merck & Co for Autoimmune Diseases

Shots: BioMed and Merck & Co (MSD outside the United States and Canada) signs an agreement and extends their ongoing collaboration for six joint research projects at BioMed X Innovation Center in Heidelberg, Germany The focus of the agreement is to concentrate on the role of intestinal epithelial barrier in the development and exacerbation of […]Read More

AbbVie Collaborates with Dragonfly Therapeutics to Develop Therapies for Autoimmune

Shots: Dragonfly to receive upfront, milestones and royalties on licensed therapies. AbbVie to get an exclusive option to license global intellectual property rights to develop and commercialize therapies developed during the collaboration Dragonfly will utilize its TriNKET platform for developing therapies targeting multiple autoimmune and oncology indications Dragonfly’s novel TriNKET technology acts by enhancing immunotherapy […]Read More

Eli Lilly Collaborates with Aduro Biotech for its cGAS-STING Pathway

Shots: Aduro to receive $12M upfront, up to $620M milestones and royalties on sales from Lilly. Lilly to get rights for Aduro’s cGAS-STING pathway inhibitor program and will be responsible for all costs for its global commercialization Lilly to fund the research program, Aduro will be responsible for the research of molecules in cGAS-STING Pathway Inhibitor Program with an option […]Read More

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots: Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and […]Read More

Sandoz’s Hyrimoz (adalimumab) Receives EU Approval for Autoimmune Disorders

Shots: The approval is based on non-inferiority data assessing Hyrimoz vs reference biologic in patients with rheumatoid arthritis, plaque psoriasis, Crohn’s disease, uveitis and ulcerative colitis The study demonstrated in meeting al 1EPs and resulted bioequivalence in terms of safety, efficacy, PK, immunogenicity in patients with moderate to severe chronic plaque-type psoriasis Hyrimoz (adalimumab) is […]Read More